Alnylam Pharmaceuticals (ALNY) has disclosed a new risk, in the International Operations category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alnylam Pharmaceuticals faces material execution risk in scaling its global footprint to match its Alnylam 2030 ambitions, particularly as it commercializes AMVUTTRA in ATTR-CM and broadens its pipeline. The rapid expansion of headcount and geographies strains existing infrastructure, and any delay or shortfall in building operational, regulatory, and commercial capabilities, or in enhancing control systems, could impair growth and disrupt global product launches.
The average ALNY stock price target is $474.00, implying 53.66% upside potential.
To learn more about Alnylam Pharmaceuticals’ risk factors, click here.